Enteris BioPharma is a clinical-stage biopharmaceutical company that provides innovative formulation solutions centred around its proprietary drug delivery technologies, peptelligence and properma. The company offers end-to-end oral drug product development, ranging from formulation and proof-of-concept through to clinical and commercial manufacturing for the most challenging Active Pharmaceutical Ingredients (APIs). Enteris BioPharma’s services are designed to address the complexities of drug development, with a focus on enhancing the bioavailability and delivery of pharmaceuticals.

Services include:
- 505(b)(2)
- Analytical Services
- Drug Delivery Devices
- Feasibility Studies
- Filling
- Capsule
- Process Development
- Formulation Development
- Controlled Release
- Manufacturing
- Cytotoxic & High Potency Compounds
- Dose Form
- Non-Sterile
- Microbial-based Therapeutic Proteins
- Nasal Delivery
- Tablets
- Quality QA/QC

Enteris BioPharma continues to advance the field of biopharmaceuticals through its specialised capabilities and commitment to innovation. For more information, visit enterisbiopharma.com.